cdk8 — TargetMol Chemicals

Cat No.	Product Name	Targets
T72029	CDK8-IN-13	Apoptosis , CDK
	CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity...	Apoptosis , CDK
T10740	CDK8-IN-1	CDK
	CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).	CDK
T72048	CDK8-IN-12	GSK-3 , CDK
	CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showe...	GSK-3 , CDK
T10739	CDK8/19-IN-1	CDK
	CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).	CDK
T70148	CDK8-IN-4k
	CDK8-IN-4k is a potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition.
T17305	CDK8-IN-4	CDK
	CDK8-IN-4 is an inhibitor of CDK8 (IC50: 0.2 nM).	CDK
T14917	CDK8-IN-3	Others
	CDK8-IN-3 is an inhibitor of CDK8.	Others
T70098	CDK8-IN-18
	CDK8-IN-18, also known as ZINC584617986, is a potent and selective inhibitor of CDK8, also modulating CDK19.
T62310	CDK8-IN-5
	CDK8-IN-5 is a potent inhibitor of CDK8, exhibiting an inhibitory concentration (IC 50) of 72 nM. Demonstrating anti-inflammatory properties, it achieves a 43% enhancement rate of IL-10. This compound holds potential for...
T62112	CDK8-IN-6
	CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers.
T63690	CDK8-IN-10
	CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.
T61742	CDK8-IN-11
	CDK8-IN-11 is a potent and selective inhibitor of CDK8, demonstrating an IC50 of 46 nM, and effectively targets the WNT/β-catenin signaling pathway. This compound has potential applications in colon cancer research [1].
T64245	CDK8-IN-9
	CDK8-IN-9 (compound 22) is a potent inhibitor of type II CDK8 (IC50: 48.6 nM) and has shown inhibitory effects on tumour growth. CDK8-IN-9 can be used to study colorectal cancer.
T62354	CDK8-IN-7
	CDK8-IN-7 (compound 12) is a potent and selective inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 3.5 nM). CDK8-IN-7 has shown potential for AML-cancer research.
T62293	CDK8-IN-11 hydrochloride
	CDK8-IN-11 hydrochloride is a selective and potent inhibitor of CDK8 (IC50: 46 nM). CDK8-IN-11 hydrochloride inhibits the WNT/β-catenin signalling pathway. CDK8-IN-11 hydrochloride can be used to study colon cancer.
T71908	NU1085
	NU1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs. The biological effects of NU1085 [Ki = 6 nM], in combinati...
T21678	3MB-PP1	PLK
	3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifi...	PLK
T70147	Fipravirimat
	Fipravirimat is a potent inhibitor of HIV-1 with potential applications in HIV and AIDS research.
T14778	BRD6989	IL Receptor , CDK , Interleukin
	BRD6989 is an analog of the natural product cortistatin A (dCA). Which inhibits CDK8 and upregulates IL-10. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes. BRD6989 selectively binds a complex...	IL Receptor , CDK , Interleukin
T8430	Senexin B	CDK
	Senexin B is a potent and selective inhibitor of CDK8/19(CDK8 and CDK19 with Kds of 140 nM and 80 nM).	CDK